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Abstract. PNL2 is a recently generated monoclonal antibody (mAb) that recognizes normal and
neoplastic melanocytes. Although the antigen recognized by PNL2 remains unknown, recent studies of human
and mouse melanomas have confirmed its usefulness as a diagnostic marker. In the current study, the
immunoreactivity of PNL2 in canine melanomas was tested and compared with Melan A (A103). Validation
of PNL2 was performed by Western blot analysis. PNL2 and Melan A immunoreactivity were tested on frozen
samples of canine melanomas and on 69 formalin-fixed, paraffin-embedded melanocytic neoplasms. Normal
canine tissues and nonmelanocytic neoplasms were included as negative controls. Western blot confirmed the
presence of a protein recognized by the PNL2 antibody in canine melanomas. Immunohistochemically, PNL2
stained the melanocytic neoplastic cells with an intracytoplasmic, granular pattern. Among the melanocytic
neoplasms tested, 62% stained positively with PNL2 and 59% with Melan A; 50.7% stained positively with
both mAbs. The overall percentage of neoplasms that stained positively with at least 1 of these 2 antibodies
was 68%. The extent of staining (i.e., the percentage of cells stained per specimen) was greater with PNL2 than
with Melan A. With both mAbs, staining was most intense and diffuse in the epithelioid cell phenotype.
Neither nonspecific staining nor staining in cells other than melanocytes was detected with either mAb. In
contrast to human granulocytes, canine granulocytes were negative by both Western blot and
immunohistochemical analyses. PNL2 mAb proved to be highly specific for the identification of formalin-
fixed canine melanocytic neoplasms and should be a valuable diagnostic reagent.
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Introduction
Histologic diagnosis of melanoma can be challeng-
ing, especially when pathologists are facing amela-
notic or metastatic lesions. In consequence, immuno-
histochemical staining is often necessary for a defini-
tive diagnosis. For several years, antibodies against
S100 proteins and HMB45 have been used extensively
in human pathology.12,21 In veterinary pathology,
however, HMB45 monoclonal antibody (mAb) has
been applied only rarely, and its use on canine tissues
requires an elaborate antigen unmasking tech-
nique.14,17,19 More recently, a number of novel mAbs
that recognize formalin-resistant melanocytic differ-
entiation antigens have become available in human
and veterinarypathology, including Melan A/MART 1
(clone A103/M2-7C10), anti-tyrosinase (T311), and
microphthalmia transcription factor (D5).4,6,7,9
Melan A/MART 1 is one of the most extensively
used mAbs in both human and veterinary pathology
diagnostics. It is a melanocyte-differentiating protein
that is recognized by tumor-infiltrating human cyto-
toxic T lymphocytes. Melan A is expressed by normal
human melanocytes, benign nevi, melanomas, and, less
frequently, desmoplastic human melanomas. In 2
independent studies,1,2 benign melanocytic lesions had
a higher overall percentage of positively stained cells
compared with malignant lesions. In a single study on
canine tissues,7 the intensity of Melan A staining was
also positively correlated with biologic behavior; more
differentiated neoplasms staining more diffusely and
intensely than amelanotic, undifferentiated ones.
A novel mAb recognizing melanocytes, designated
PNL2, was recently generated.16 Originally created to
detect a subtype of human somatostatin, a few recent
studies8,10,11,16 have shown that PNL2 reacts with
normal and neoplastic human and murine melano-
cytes in both benign and malignant lesions. Although
the protein target of PNL2 remains to be identified,
the results from these different studies suggest PNL2
is a very useful marker for the immunohistochemical
diagnosis of melanocytic lesions.
The aims of the present study were to verify the
usefulness of PNL2 in the immunohistochemical
From the Dipartimento di Patologia, Igiene e Sanita` Pubblica
Veterinaria (Giudice, Ceciliani, Rondena, Grieco) and the
Dipartimento di Scienze Cliniche Veterinarie (Stefanello), Facolta`
di Medicina Veterinaria, Universita` degli Studi di Milano, Milano,
Italy.
1 Corresponding Author: Chiara Giudice, Department of
Veterinary Pathology, Hygiene and Public Health, Via Celoria,
10, 20133 Milano, Italy. chiara.giudice@unimi.it
J Vet Diagn Invest 22:389–394 (2010)
389
diagnosis of formalin-fixed, paraffin-embedded ca-
nine melanocytic neoplasms and to compare PNL2
and Melan A immunostaining. In the first step, the
cross-reactivity of the antibody was investigated by
Western blot (WB) in both human and canine
melanomas. In the second step, the immunoreactivity
of PNL2 in canine melanoma was assessed by
immunohistochemistry.
Materials and methods
Western blot validation of PNL2 antibody against dog tissues
Western blot analysis was conducted using tissue
homogenates of canine melanoma and neutrophils
(PMNs). Human neutrophils, obtained from healthy
donors and previously reported to specifically react with
PNL2,16 as well as samples of human melanoma, were used
as positive controls.
Melanoma samples were collected by routine surgery and
were immediately processed for protein extraction. An
aliquot of 50–100 mg of fresh tissue was mechanically
homogenized in 10-fold volumes (w/v) of cold lysis buffer
(50 mM Tris–HCl, pH 7.6, 150 mM NaCl, 4% NP40, 2%
Triton X-100, 1% zwitterion 3.14, 5 mM ethylenediamine
tetra-acetic acid [EDTA]). A cocktail of protease inhibitorsa
was then added to each aliquot, which were left on ice for
30 min. To improve mincing, the tissues were mechanically
homogenized again, and then centrifuged for 10 min at
14,000 3 g. The supernatant was collected and protein
concentration was determined by ultraviolet spectrophoto-
metry (l 5 A280). Dog and human PMNs (1 3 10
7) were
purified following previously described protocols.20,22
Human circulating PMNs were purified from peripheral
blood of healthy donors as previously reported20 with some
modifications. The PMNs were isolated by sedimentation
in 2% dextrana in Hanks’ balanced buffer 1% for 1 hr at
room temperature and centrifugeda at 400 3 g for 30 min.
Remaining erythrocytes were removed from the pellet of
PMNs by hypotonic lysis using red blood cell lysis buffera
at 37uC for 5 min. The PMNs were then washed twice with
ice-cold phosphate buffered saline (PBS), counted with an
automated hematology analyzer, and suspended in ice-cold
PBS at a concentration of 1 3 106 cells/ml. The purity of
the neutrophils suspension was .95%, as determined by
morphological evaluation. Cell viability was .98%, as
determined by the Trypan blue exclusion test. The cells
were subsequently centrifuged at 400 3 g at 4uC and
resuspended at a concentration of 1 3 108 cells/ml. An
aliquot of 100 ml of this suspension was used for WB
analysis. Circulating canine PMNs were purified from
peripheral blood of healthy animals as previously re-
ported,22 with some modifications. Heparinized whole
blood was collected from the cephalic vein, and erythro-
cytes were depleted by dextran sedimentation (6%, w/v).
The leukocyte-rich supernatant was then collected and
further centrifuged on a Ficoll density gradient (1.077) at
400 3 g for 30 min at 4uC. The PMN fraction was
harvested, and contaminating erythrocytes were removed
by lysis at 37uC for 5 min. The PMNs were then washed
twice with PBS and processed as described for human
PMNs.
Immunoreactivity was tested on different concentrations
of tissue and PMN lysates ranging from 5 to 20 mg of total
protein content that were electrophoresed in a 12% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and
transferred to a nitrocellulose membrane for Western blot
analysis. Immunodetection was done for 1 hr at room
temperature using PNL2 mAb at a concentration ranging
from 1:100 to 1:2,000 of the stock solution. A horseradish
peroxidase (HRP)-conjugated antimouse secondary anti-
bodya was used (1:2,000 dilution) to localize sites of PNL2
binding and the positive bands were detected using
chemiluminescent HRP substrate.b
Immunohistochemistry
Immunohistochemical staining was performed initially
on frozen melanoma specimens and subsequently on
formalin-fixed, paraffin-embedded samples. Frozen sam-
ples were used to assess the intracellular localization of
PNL2 in nondenaturing conditions (i.e., without antigen
retrieval application).
Four primary canine melanomas (2 oral melanomas and
2 nail-bed melanomas), previously diagnosed by cytology,
were surgically obtained and immediately frozen in liquid
nitrogen (2196uC). Serial frozen sections (7 mm thick) were
prepared, fixed in cold acetone (220uC) for 2 min, and then
immunostained with anti–Melan A (clone A 103, mouse
IgG1)c and anti-PNL2 (clone PNL2, mouse immunoglo-
bulin G1 kappa)d mAbs using a standard avidin–biotin–
peroxidase complex (ABC) method.5 Endogenous perox-
idase activity was blocked with 0.3% hydrogen peroxide in
0.01 M Tris buffer saline (TBS; pH 7.4) for 30 min. Slides
were then rinsed in TBS and incubated at room tempera-
ture (RT) for 30 min with TBS containing 10% normal
horse serum to block nonspecific protein binding. Finally,
slides were incubated overnight in a humidified chamber at
4uC with the primary antibodies. Various serial dilutions
were tested for both primary antibodies, and a dilution of
1:25 was selected as providing optimal immunostaining
results.
After three 5-min rinses in TBS, the tissue sections were
incubated with antimouse biotinylated secondary antibodye
for 30 min at RT. After washing 3 times in TBS, the tissue
sections were incubated with ABC for 30 min at RT, and
then rinsed 3 times in TBS. The chromogen, 3-amino-9-
ethylcarbazole,e was then applied for 15 min. After rinsing
in tap water, slides were counterstained with Mayer
hematoxylinf for 1 min and mounted with glycerin jelly.g
Sixty-nine formalin-fixed, paraffin-embedded canine
melanocytic neoplasms submitted between 2002 and 2004
were selected from the archives of the section of Veterinary
Pathology of the University of Milan (Milan, Italy).
Clinical information, including signalment data and tumor
location, was available for all samples. Hematoxylin and
eosin–stained slides were reviewed, and the cell type
(epithelioid, spindle, mixed) was recorded. The predomi-
nant cell type was assigned for neoplasms in which one cell
type constituted less than 5% of the tumor mass.
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Serial sections were obtained from paraffin blocks and
immunostained with anti–Melan A and anti-PNL2 mAbs
(dilution 1:25), using the same ABC protocol used for
frozen sections. After dewaxing in xylene and rehydration
through a descending series of ethanol solutions, endogen-
ous peroxidase activity was blocked with 0.3% hydrogen
peroxide in methanol for 45 min. Antigen retrieval was
performed using various methods of heat retrieval and
buffer pH concentrations that were tested on positive
control tissues (i.e., neoplasms for which a nitrogen-frozen
portion was previously obtained and which had positive
immunostaining). Optimal staining on control tissues was
obtained by heating slides in a pressure steamer for 10 min
in an EDTA buffer solution (pH 8.0); this protocol was
subsequently applied to all tissue specimens. After antigen
retrieval, the tissue sections were allowed to cool for 40 min
and were then rinsed in TBS.
Because PNL2 is a protein of unknown function whose
expression has never been previously investigated in the
canine specimens, a wide variety of normal canine tissues
and nonmelanocytic neoplasms was included in the
immunoassay as negative controls. Normal canine tissues
were included to exclude cross reactivity of PNL2 with
proteins normally expressed in these tissues. Nonmelano-
cytic neoplasms were included to test the specificity of
PLN2 for melanoma.
Microarrays of normal canine tissue were created by
assembling multiple samples (5 mm 3 5 mm 3 3 mm each)
of formalin-fixed tissue in the same paraffin block. These
normal tissues are listed in Table 1. Because Melan A has
been reported to be positive in the adrenal cortex, multiple
samples of adrenal tissue were included in different
microarrays.
For immunoassay of nonmelanocytic neoplasms, con-
ventional tissue sections were used. The neoplasms assayed
are listed in Table 2. The presence of immunostaining, its
localization within neoplastic cells, its distribution, and its
specificity for neoplastic cells were evaluated. Moreover,
the intensity of the antibody staining was subjectively
graded as weak, moderate, and intense. The extent of
immunostaining, defined as the percentage of neoplastic
cells stained, was also semiquantitatively assessed for each
antibody and graded as negative (no cells stained) or
variable degrees of positivity (,25% of the cells stained,
26–50% of the cells stained, 51–75% of the cells stained, or
.75% of the cells stained).
Results
Western blot
The reactivity of PNL2 was validated against dog
melanoma and human granulocytes, the latter serving
as positive controls. Results are presented in Fig-
ure 1A. Western blot analysis revealed that PNL2
reacted with at least 3 major bands with apparent
molecular weights (MW) of .120, 31, and ,10 kDa,
and a minor band at 62 kDa when tested against
whole dog melanoma protein extract. Human gran-
ulocytes produced 2 major bands, with a MW of 100
and 31 kDa, and a minor band at 62 kDa. The
comparison of PNL2 immunoreactivity against dog
and human melanoma is shown in Figure 1B. In both
tissues samples, a low MW band (,10 kDa) could be
detected. Figure 1B also demonstrates that immuno-
Table 1. Normal canine tissues evaluated for PNL2 and
Melan A immunostaining (tissue microarrays).
Normal tissues PNL2 Melan A
Adrenal glands (33)* Negative Negative
CNS (brain, forebrain, cerebellum){ Negative Negative
Heart Negative Negative
Kidney Negative Negative
Liver Negative Negative
Lung Negative Negative
Lymph nodes Negative Negative
Pancreas (exocrine and endocrine) Negative Negative
Salivary gland Negative Negative
Skeletal muscle Negative Negative
Skin Negative Negative
Small and large intestine Negative Negative
Spleen Negative Negative
Stomach Negative Negative
Thymus Negative Negative
Thyroid Negative Negative
* Three different samples of adrenal tissue were included in
different microarrays.
{ CNS 5 central nervous system.
Table 2. Nonmelanocytic neoplasms evaluated by PNL2 and Melan A immunostaining (conventional tissue sections were used).
Site Diagnosis No. of samples tested PNL2 Melan A
Mammary gland Carcinoma (complex type) 4 Negative Negative
Skin Carcinoma (undifferentiated) 2 Negative Negative
Skin Hemangioma, cavernous 2 Negative Negative
Skeletal muscle Hemangiosarcoma 1 Negative Negative
Subcutis Hemangiopericytoma 4 Negative Negative
Subcutis Sarcoma (fibrosarcoma) 2 Negative Negative
Vagina Sarcoma (leiomyosarcoma) 2 Negative Negative
Digit Sarcoma (synovial) 1 Negative Negative
Skin Sarcoma (undifferentiated) 1 Negative Negative
Lymph node T-cell lymphoma 1 Negative Negative
Adrenals Pheochromocytoma 1 Negative Negative
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reactivity was not detected in the homogenate
obtained from canine granulocytes.
Immunohistochemistry on frozen tissues
Canine frozen melanoma specimens had positive
staining with both PNL2 and Melan A. The
immunostaining was always cytoplasmic with both
mAbs. Specifically, immunostaining for PNL2 was
intense, finely granular, and cytoplasmic in neoplastic
cells. No background staining or staining of stromal
tissue, blood vessels, or intravascular granulocytes
was observed.
Paraffin-embedded tissues
Melanocytic neoplasms from 69 dogs were exam-
ined. Sixty-eight specimens were primary neoplasms
(39 cutaneous, 17 oral cavity, 9 mucocutaneous, 3
epibulbar), and 1 neoplasm was metastatic to a lymph
node. The cutaneous neoplasms were distributed as
follows: 9 eyelids, 7 limbs, 8 trunk, 8 head/neck, 6
nail-bed, and 1 mammary skin. Twenty-eight neo-
plasms were classified as benign (melanocytomas),
and 41 were classified as malignant (melanomas).
PNL2 immunostaining was present in 43 out of
69 melanocytic neoplasms (62%), and Melan A
immunostaining was present in 41 out of 69 (59%)
neoplasms. The overall percentage of melanocytic
neoplasms that stained positively for at least 1 of the 2
antibodies tested was 68% (47/69), while 51% of
neoplasms stained positively for both mAbs. Both
PNL 2 and Melan A stained fewer benign neoplasms
(9/28, 32%) than malignant melanomas (32/41, 78%
PNL2 positive; 34/41, 83% Melan A positive;
Table 3). No differences were observed between
PNL2 and Melan A immunostaining when the
percentage of positively stained samples was com-
pared with the primary site of the neoplasm.
The staining pattern for both PNL2 and Melan A
was exclusively cytoplasmic and limited to cells of
melanocytic lineage. Nonspecific staining was not
observed in necrotic areas or in cells other than
melanocytes. When present, PNL2 and Melan A
immunostaining was always intense (Fig. 2A, B).
The extent of immunostaining, evaluated as the
percentage of cells stained, is presented in Figure 3. In
general, PNL2 stained .75% of neoplastic cells in a
greater number of neoplasms (19/43) than Melan A
(9/41). When neoplasms were grouped by cell type,
PNL2 immunostaining was observed in 14 out of 29
spindles and 28 out of 40 epithelioid cell melanomas;
whereas Melan A stained 15 out of 29 spindles and 25
out of 40 epithelioid cell melanomas. As a general
rule, the neoplasms that stained positively for both
antibodies showed a similar distribution of immu-
nostaining (i.e., the same cells, evaluated in serial
sections, stained positively). A remarkable exception
was melanocytes at the dermoepidermal junction,
which had more frequent and intense immunostaining
with PNL2 than with Melan A.
All normal canine tissues and nonmelanocytic
neoplasms lacked staining with both antibodies
(Tables 1, 2). No PNL2 immunostaining was ob-
served in canine granulocytes within blood vessels of
normal or neoplastic tissues.
PNL2 consistently stained normal and hyperplastic
melanocytes in skin sections, whereas Melan A failed
to stain normal cutaneous melanocytes. Melan A did
Figure 1. Western blot analysis of canine and human
melanoma and of blood granulocytes; immunoblot probed with
an anti-PNL2 monoclonal antibody. A, 3 major bands of .120,
31, and ,10 kDa molecular weight (MW), and a minor band at
62 kDa are evident in the dog melanoma homogenate. Human
granulocytes produced 2 major bands with a MW of 100 and
31 kDa, and a minor band at 62 kDa. B, comparison of PNL2
immunoreactivity against dog and human melanoma shows a low
MW band (,10 kDa). No immunoreactivity was detectable in
canine granulocytes.
Table 3. Results of PNL2 and Melan A immunostaining of
benign and malignant neoplasms.
PNL2 positive Melan A positive
Benign neoplasms (28/69) 9 (32.1%) 9 (32.1%)
Malignant neoplasms (41/69) 34 (82.9%) 32 (78%)
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stain infrequent, large, intraepidermal, star-shaped
melanocytes that were occasionally present in proxi-
mity to cutaneous melanocytic neoplasms.
Discussion
The differentiation of melanomas from a variety of
poorly undifferentiated neoplasms is often challeng-
ing for pathologists. Thus, there is a need for
melanocytic markers that are resistant to formalin
fixation and readily detectable using routine immu-
nodiagnostic procedures. In recent years, an increas-
ing number of antibodies have become commercially
available for routine diagnosis of melanomas in both
veterinary and human pathology. In veterinary
pathology, the most extensively used antibodies are
S100 and Melan A because of their high sensitivity
(S100) and specificity (Melan A). Although S100 has
a sensitivity approaching 90% in several studies, it has
low specificity.4,7,15,18 In contrast, Melan A is con-
sidered highly specific but has been reported to stain
polygonal cell melanomas more consistently than
spindle cell melanomas in both canine and human
neoplasms.6,13,15
PNL2 is a mAb that has recently been introduced
as a reagent for immunohistochemical identification
of human melanocytes in formalin-fixed, paraffin-
embedded tissues.16 Although the discovery of PNL2
as a marker of melanoma cells was fortuitous and the
exact role of the PNL2 protein is still unknown,
its value in the diagnosis of human and albino
rat melanomas has been confirmed by multiple
studies.3,8,10,11
To the authors’ knowledge, this is the first study
reporting the use of PNL2 to detect canine melano-
cytic antigens. Immunostaining of canine and human
melanoma extracts with PNL2 revealed similar
reactivity, suggesting that PNL2 reacts with the same
protein in both species. Interestingly, human granu-
locytes reacted with PNL2 (a result that is consistent
with previous publications16) in the present study, but
dog granulocytes did not cross-react with this mAb.
This result was confirmed by the absence of
immunostaining of canine granulocytes in both
frozen and formalin-fixed tissues, suggesting a differ-
ent distribution of PNL2 protein in dogs.
Evaluation of a large number of formalin-fixed
canine specimens demonstrated high specificity of
PNL2 for canine melanocytes, staining 62% of the
specimens tested. In the present cohort of cases, the
percentage of melanocytic neoplasms stained by
PNL2 (62%) was only slightly higher than those
positive for Melan A (59%). Interestingly, a higher
percentage of neoplasms (68%) were identified as
melanocytic neoplasms when both mAbs were applied
than when either antibody was used alone.
Figure 2. Formalin-fixed, paraffin-embedded tissue sections
of eyelid dermal canine melanocytoma immunostained with
monoclonal anti–Melan A (A) and anti-PNL2 (B) antibodies.
Both antibodies gave an intense intracytoplasmic positive reaction
in a subset of neoplastic cells. Positive immunostaining appears as
finely granular, red staining within neoplastic cells. No back-
ground staining was present. 3-amino-9-ethylcarbazole chromo-
gen. Bar 5 150 micron.
Figure 3. Graphic representation of the extent of immuno-
staining (percentage of cells stained with each antibody tested).
PNL2 stained more than 75% of neoplastic cells in a greater
number of tumors (19/43) than did Melan A (9/41).
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When compared with Melan A, PNL2 detected a
higher percentage of neoplasms where more than 75%
of the neoplastic cells stained (44% with PNL2 vs.
22% with Melan A). This may confer an important
advantage when small biopsy samples are examined.
Unfortunately, both PNL2 and Melan A stained
epithelioid cell melanomas more frequently than
spindle cell melanomas. Thus, the ability to differ-
entiate spindle cell amelanotic melanomas from other
spindle cell sarcomas is still unresolved. Notwith-
standing, the high specificity and sensitivity of PNL2
make this novel mAb an important addition to the
panel of antimelanoma antibodies for the routine
diagnosis of canine melanocytic neoplasms in for-
malin-fixed, paraffin-embedded tissue sections.
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